Maze Therapeutics Inc
MAZE42.100USD
+0.020+0.05%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
2.02BMarket Cap
LossP/E TTM
More Details of Maze Therapeutics Inc Company
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Maze Therapeutics Inc Info
Ticker SymbolMAZE
Company nameMaze Therapeutics Inc
IPO dateJan 31, 2025
CEOColoma (Jason V)
Number of employees125
Security typeOrdinary Share
Fiscal year-endJan 31
Address171 Oyster Point Boulevard, Suite 300
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16508505070
Websitehttps://www.mazetx.com/
Ticker SymbolMAZE
IPO dateJan 31, 2025
CEOColoma (Jason V)
Company Executives of Maze Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Mr. Neil Exter
Mr. Neil Exter
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Independent Director
Independent Director
--
-100.00%
Ms. Jillian Connell
Ms. Jillian Connell
Investor Relations
Investor Relations
--
--
Dr. Jamie Brush, M.D.
Dr. Jamie Brush, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Mr. Neil Exter
Mr. Neil Exter
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Revenue Breakdown
FY2025Q2
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
11.27%
Frazier Life Sciences Management, L.P.
9.49%
ARCH Venture Partners
8.56%
Deep Track Capital LP
8.21%
Alphabet, Inc.
5.01%
Other
57.45%
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
11.27%
Frazier Life Sciences Management, L.P.
9.49%
ARCH Venture Partners
8.56%
Deep Track Capital LP
8.21%
Alphabet, Inc.
5.01%
Other
57.45%
Shareholder Types
Shareholders
Proportion
Venture Capital
35.70%
Hedge Fund
16.44%
Investment Advisor/Hedge Fund
13.10%
Private Equity
10.76%
Investment Advisor
8.45%
Individual Investor
1.88%
Family Office
1.00%
Research Firm
0.45%
Endowment Fund
0.19%
Other
12.01%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
111
39.53M
83.57%
-194.63K
2025Q2
100
42.58M
97.22%
+13.88M
2025Q1
93
44.69M
102.04%
+15.27M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Third Rock Ventures, LLC
7.02M
16.02%
--
--
Jun 30, 2025
Frazier Life Sciences Management, L.P.
4.57M
10.42%
+115.94K
+2.60%
Jun 30, 2025
ARCH Venture Partners
4.12M
9.4%
--
--
Jun 30, 2025
Deep Track Capital LP
3.95M
9.01%
+679.78K
+20.79%
Jun 30, 2025
Alphabet, Inc.
2.41M
5.5%
--
--
Jun 30, 2025
Andreessen Horowitz
1.70M
3.88%
--
--
Jun 30, 2025
Matrix Capital Management Company, LP
2.49M
5.67%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
419.61K
0.96%
-246.94K
-37.05%
Jun 30, 2025
Logos Global Management LP
611.91K
1.4%
-325.00K
-34.69%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.64%
Invesco Dorsey Wright SmallCap Momentum ETF
0.53%
ALPS Medical Breakthroughs ETF
0.39%
iShares Micro-Cap ETF
0.12%
iShares Russell 2000 Value ETF
0.04%
ProShares UltraPro Russell2000
0.03%
ProShares Hedge Replication ETF
0.03%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
Schwab U.S. Small-Cap ETF
0.02%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.64%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.53%
ALPS Medical Breakthroughs ETF
Proportion0.39%
iShares Micro-Cap ETF
Proportion0.12%
iShares Russell 2000 Value ETF
Proportion0.04%
ProShares UltraPro Russell2000
Proportion0.03%
ProShares Hedge Replication ETF
Proportion0.03%
iShares Russell 2000 ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Maze Therapeutics Inc?
The top five shareholders of Maze Therapeutics Inc are:
Third Rock Ventures, LLC holds 7.02M shares, accounting for 16.02% of the total shares.
Frazier Life Sciences Management, L.P. holds 4.57M shares, accounting for 10.42% of the total shares.
ARCH Venture Partners holds 4.12M shares, accounting for 9.40% of the total shares.
Deep Track Capital LP holds 3.95M shares, accounting for 9.01% of the total shares.
Alphabet, Inc. holds 2.41M shares, accounting for 5.50% of the total shares.
Third Rock Ventures, LLC holds 7.02M shares, accounting for 16.02% of the total shares.
Frazier Life Sciences Management, L.P. holds 4.57M shares, accounting for 10.42% of the total shares.
ARCH Venture Partners holds 4.12M shares, accounting for 9.40% of the total shares.
Deep Track Capital LP holds 3.95M shares, accounting for 9.01% of the total shares.
Alphabet, Inc. holds 2.41M shares, accounting for 5.50% of the total shares.
What are the top three shareholder types of Maze Therapeutics Inc?
The top three shareholder types of Maze Therapeutics Inc are:
Third Rock Ventures, LLC
Frazier Life Sciences Management, L.P.
ARCH Venture Partners
Third Rock Ventures, LLC
Frazier Life Sciences Management, L.P.
ARCH Venture Partners
How many institutions hold shares of Maze Therapeutics Inc (MAZE)?
As of 2025Q3, 111 institutions hold shares of Maze Therapeutics Inc, with a combined market value of approximately 39.53M, accounting for 83.57% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -13.65%.
What is the biggest source of revenue for Maze Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Maze Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
